OAB-14

OAB-14

O656128-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

OAB-14, is a Bexarotene derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice. In Vivo OAB-14 significantly alleviates cognitive impairments in amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic mice after administration for 15 days or 3 months. OAB-14 rapidly cleared 71% of Aβ by promoting microglia phagocytosis and increasing IDE and NEP expression. OAB-14 also attenuates the downstream pathological events of Aβ accumulation, such as synaptic degeneration, neuronal loss, tau hyperphosphorylation and neuroinflammation in APP/PS1 mice. OAB-14 has no significant effect on body weight or liver toxicity after acute and chronic treatment . OAB-14 facilitates receptor-mediated endocytosis and restores autophagy flux via the AMPK/mTOR pathway. OAB-14 enhances the lysosomal activity, and reduced Aβ accumulation in lysosomes is observed in OAB-14-treated AD mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

OAB-14 是一种贝沙罗汀（HY-14171）衍生物，通过增加 APP/PS1 小鼠的 β 淀粉样蛋白清除率，改善阿尔茨海默病相关病理和认知障碍。OAB-14 能有效改善内体-自噬-溶酶体的功能障碍。

2140911-49-3(DMSO)

C32H46N4O2

518.73 g/mol

O=C(NCCN)NC1=CC=C(C(NC2=C(C(C)(CCC3(C)C)C)C3=CC4=C2C(C)(C)CCC4(C)C)=O)C=C1